Literature DB >> 18476790

Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders.

Maurício de Maio1.   

Abstract

BACKGROUND: The therapeutic uses of botulinum toxin have been expanding due to deeper knowledge of its molecular behaviour and different mechanisms of action.
OBJECTIVE: To present suggested doses of Botox and Dysport for controlling the muscle hyperkinetic activity in facial palsy in the perioral area and to review other uses.
METHODS: An extensive updated literature review on the success and limits of the botulinum neurotoxin (BoNT) therapeutic treatments. RESULTS/
CONCLUSION: BoNT can be considered to be the preferred single method for many disorders; it has substituted for some conventional surgical methods and it can be associated with other therapies to increase overall treatment performance. Depending on the disorder, the lack of permanent effect causes no major inconvenience.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18476790     DOI: 10.1517/14712598.8.6.791

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  15 in total

1.  Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.

Authors:  M Brown; G Nicholson; M C Ardila; A Satorius; R S Broide; K Clarke; T Hunt; J Francis
Journal:  J Neural Transm (Vienna)       Date:  2012-07-29       Impact factor: 3.575

Review 2.  Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.

Authors:  Roberta Ravenni; Domenico De Grandis; Alberto Mazza
Journal:  Neurol Sci       Date:  2013-04-11       Impact factor: 3.307

3.  Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.

Authors:  Ewa Bomba-Warczak; Jason D Vevea; Joel M Brittain; Annette Figueroa-Bernier; William H Tepp; Eric A Johnson; Felix L Yeh; Edwin R Chapman
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

4.  Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Authors:  James C Burnett; Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald Moir; Sina Bavari; Terry Bowlin
Journal:  Open Access Bioinformatics       Date:  2010-04-01

5.  Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo.

Authors:  Corina Rosales; Daming Tang; Baiba K Gillard; Harry S Courtney; Henry J Pownall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05-19       Impact factor: 8.311

Review 6.  The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.

Authors:  Harry S Courtney; Henry J Pownall
Journal:  J Biomed Biotechnol       Date:  2010-07-08

7.  Ultrastructural evaluation of intramuscular applied botulinum toxin type A in striated muscles of rats.

Authors:  H Kocaelli; M Yaltirik; M Ayhan; F Aktar; B Atalay; S Yalcin
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

8.  Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors.

Authors:  Gordon Ruthel; James C Burnett; Jonathan E Nuss; Laura M Wanner; Lyal E Tressler; Edna Torres-Melendez; Sarah J Sandwick; Cary J Retterer; Sina Bavari
Journal:  Toxins (Basel)       Date:  2011-03-15       Impact factor: 4.546

9.  Endomicroscopy and electromyography of neuromuscular junctions in situ.

Authors:  Rosalind Brown; Kosala N Dissanayake; Paul A Skehel; Richard R Ribchester
Journal:  Ann Clin Transl Neurol       Date:  2014-10-10       Impact factor: 4.511

10.  Botulinum toxin related research in maxillofacial plastic and reconstructive surgery.

Authors:  Tae-Geon Kwon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2016-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.